Superworth

Adaptive Biotechnologies EPS ADPT

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$0.41
Latest quarter, Q2 FY26
−$0.25
Fiscal year 2025
−$0.40

Adaptive Biotechnologies' earnings per share was −$0.41 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.25.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.40n/a
FY2024−$1.09n/a
FY2023−$1.56n/a
FY2022−$1.41n/a
FY2021−$1.47n/a
FY2020−$1.11n/a
FY2019−$2.96n/a
FY2018−$3.68n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.25n/a−$0.41
Q1 FY26−$0.13n/a−$0.33
Q4 FY25−$0.09n/a−$0.40
Q3 FY25$0.06n/a−$0.54
Q2 FY25−$0.17n/a−$0.82
Q1 FY25−$0.20n/a−$0.96
Q4 FY24−$0.23n/a−$1.09
Q3 FY24−$0.22n/a−$1.34
Q2 FY24−$0.31n/a−$1.47
Q1 FY24−$0.33n/a−$1.49
Q4 FY23−$0.48n/a−$1.56
Q3 FY23−$0.35n/a−$1.36

Against its peers

Companies in Biotechnology nearest Adaptive Biotechnologies' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ADPTAdaptive Biotechnologies−$0.41
ADMAAdma Biologics$0.70−18% a year
VCELVericel$0.46+283% a year
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
MGTXMeiraGTx$0.71
INCYIncyte$7.85+78% a year
Peer median$2.17

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Adaptive Biotechnologies

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.